Literature DB >> 6973130

Pharmacokinetic comparison of intravenous and oral chloramphenicol in patients with Haemophilus influenzae meningitis.

R Yogev, W M Kolling, T Williams.   

Abstract

The pharmacokinetics of chloramphenicol following intravenous and oral administration were studied in 14 infants with Haemophilus influenzae meningitis. Following five days of treatment with intravenous chloramphenicol (100 mg/kg/day every six hours), oral chloramphenicol was substituted at the same dose. Multiple serum levels of chloramphenicol were determined after an intravenous dose on day 4 and after an oral dose on day 10. CSF levels were measured six hours after intravenous or oral chloramphenicol dose on those days (CSF trough). Following intravenous administration, the mean peak serum level of 15.0 micrograms/ml was reached at 45 minutes. In comparison, after oral chloramphenicol in the same dosage, the mean peak serum level of 18.5 micrograms/ml was achieved at two to three hours. The mean serum half-life of the drug (6.5 hours) was significantly longer after oral administration than after intravenous chloramphenicol (4.0 hours) (P less than .001). The increased serum half-life following orally administered chloramphenicol was occasionally associated with drug accumulation. In addition, mean trough CSF levels were somewhat higher when the patient received oral medication (6.6 micrograms/ml) compared to intravenous administration (4.2 micrograms/ml) (P less than .001). For any treatment regimen for H influenzae meningitis that includes a period of oral chloramphenicol therapy the patient should be hospitalized to ensure compliance. Because of the wide range of individual variation in serum half-life that may result in accumulation, periodic monitoring of serum chloramphenicol levels is also recommended.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6973130

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

1.  Combined action of chloramphenicol and ampicillin on chloramphenicol-resistant Haemophilus influenzae.

Authors:  A M Mackenzie; F T Chan
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

2.  Novel approaches to therapy of meningitis.

Authors:  G H McCracken
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

3.  Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid.

Authors:  Marija Djukic; Martin Munz; Fritz Sörgel; Ulrike Holzgrabe; Helmut Eiffert; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

4.  Diglycine Enables Rapid Intrabacterial Hydrolysis for Activating Anbiotics against Gram-negative Bacteria.

Authors:  Jiaqing Wang; Deani L Cooper; Wenjun Zhan; Difei Wu; Hongjian He; Shenghuan Sun; Susan T Lovett; Bing Xu
Journal:  Angew Chem Int Ed Engl       Date:  2019-06-27       Impact factor: 15.336

5.  Sequential antibiotic therapy: Effective cost management and patient care.

Authors:  L A Mandell; M G Bergeron; M J Gribble; P J Jewesson; D E Low; T J Marrie; L E Nicolle
Journal:  Can J Infect Dis       Date:  1995-11

6.  Antibiotic therapy for bacterial meningitis in children in developing countries.

Authors:  P Kumar; I C Verma
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

Review 7.  Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate.

Authors:  P J Ambrose
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

8.  Chloramphenicol inhibition of the bactericidal effect of ampicillin against Haemophilus influenzae.

Authors:  V Rocco; G Overturf
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

9.  Chloramphenicol pharmacokinetics in Ethiopian children of differing nutritional status.

Authors:  M Eriksson; L Paalzow; P Bolme; T W Mariam
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.